AKT1 and glioblastoma: The present methodology for obtaining astrocyte-derived cells that present traits of malignancy, with activation of both the PI3K/AKT and Wnt/β-catenin pathways, may help to test further combination therapeutic strategies targeting pivotal signaling pathways in the search for synergistic effects in GBM.